Zobrazeno 1 - 10
of 74
pro vyhledávání: ''
Autor:
Hiroshi Uchi, Satoshi Fukushima, Yuki Yamamoto, Shigeto Matsushita, Hiroshi Kato, Yasuhiro Fujisawa, Ryo Amagai, Takeo Maekawa, Kentaro Ohuchi, Yusuke Muto, Yumi Kambayashi, Koji Yoshino, Taku Fujimura
Publikováno v:
Melanoma Research. 31:575-578
Patients with resected stage IIIB, IIIC and IIID melanomas have a high risk of recurrence. Therefore, an appropriate protocol for stage III melanoma is needed. Since adjuvant dabrafenib plus trametinib (D+T) combined therapy and anti-PD1 antibody (Ab
Autor:
Gina Klee, Patrick Terheyden, Jonas K. Kurzhals, Victoria Hagelstein, Detlef Zillikens, Ewan A. Langan, Andreas Recke
Publikováno v:
Melanoma Research. 31:464-471
Combined immunotherapy is associated with a significant risk of severe and potentially fatal immune-related adverse events (irAEs). Therefore, we retrospectively analyzed the side profile and efficacy of low-dose ipilimumab (1 mg/kg, IPI1) combined w
Publikováno v:
Melanoma Research. 31:242-248
Twenty to sixty percent of patients receiving immune checkpoint inhibitors (ICIs) experience high-grade immune-related adverse events (irAEs) which may prevent the continuation of treatment. Limited clinical evidence is available to guide treatment f
Autor:
Bożena Cybulska-Stopa, Piotr Rutkowski, Jacek Calik, Natasza Kempa-Kamińska, Anna M. Czarnecka, Barbara Ziółkowska, Marcin Ziętek, Jacek Mackiewicz, Łukasz Galus, Tomasz Zemełka, Tomasz Kubiatowski, Stanisław Kieszko, Karolina Piejko, Grażyna Kamińska-Winciorek, Rafał Suwiński
Publikováno v:
Melanoma Research. 31:49-57
Immunotherapy with anti-programmed cell death-1 (PD-1) agents is an effective treatment for metastatic melanoma. Octogenarians and nonagenarians represent a significant cohort of melanoma patients. This multicenter retrospective analysis enrolled 499
Autor:
Victor Traves, Esperanza Manrique-Silva, Celia Requena, Oscar M. Moreno-Arrones, Michael Gerbo, Josh Zegeer, Eduardo Nagore
Publikováno v:
Melanoma Research. 29:664-667
The aim of this study is to evaluate the relation between 25-hydroxyvitamin D levels at diagnosis and pathological characteristics in primary invasive melanoma. A cross-sectional study was designed based on a series of 204 consecutive patients diagno
Autor:
Danielle S. Comissiong, Joshua T. Cohen, Andrew M. Blakely, Michael P. Vezeridis, Thomas J. Miner
Publikováno v:
American Journal of Clinical Oncology. 42:824-829
Objectives Thick melanomas, defined as ≥4 mm in thickness, represent ~5% of new melanoma diagnoses and have been associated with poor overall survival (OS). Ultrathick melanomas, those lesions ≥8 mm in thickness, have been associated with worse s
Autor:
Christian U. Blank, Johannes V. Van Thienen, Dieta Brandsma, John B. A. G. Haanen, Willem Boogerd, Marnix H Geukes Foppen
Publikováno v:
Melanoma Research. 28:126-133
Patients with brain metastases (BM) from melanoma have an overall survival (OS) of 2-6 months after whole-brain radiotherapy. Targeted therapy (TT) is an effective treatment for BRAF-mutated metastatic melanoma. Moreover, recent studies indicate intr
Autor:
Faruk Tas, Kayhan Erturk
Publikováno v:
Melanoma Research. 27:387-390
A small subset of head and neck melanoma, scalp melanoma comprises 3-5% of all cutaneous melanomas. So far, small numbers of researches on scalp melanoma have yielded controversial results. In this trial, we aimed to define the histopathological and
Autor:
Martine Bagot, Barouyr Baroudjian, Céleste Lebbé, Nelson Lourenco, Marianne Maillet, Philippe Bertheau, Matthieu Allez, Cécile Pagès, Ichrak Chami, Jean-Marc Gornet
Publikováno v:
Melanoma Research. 26:308-311
Targeted immunotherapy has markedly improved the survival of melanoma patients. We report the case of a melanoma patient who developed a collagenous colitis under an anti-PD1 regimen. A 68-year-old woman was treated for a stage IV melanoma. An anti-P
Publikováno v:
Journal of Immunotherapy. 41:411-412
Introduction Ipilimumab and nivolumab are immune-checkpoint inhibitors commonly used for melanoma. The combination is being investigated for its efficacy against several types of cancer, including malignant pleural mesothelioma. Although immune-relat